MedKoo Cat#: 574769 | Name: Leu-AMS
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Leu-AMS is a leucine analogue and inhibitor of leucyl-tRNA synthetase (LRS). Leu-AMS displays cytotoxicity in cancer cells and normal cells and inhibits the growth of bacteria.

Chemical Structure

Leu-AMS
Leu-AMS
CAS#288591-93-5

Theoretical Analysis

MedKoo Cat#: 574769

Name: Leu-AMS

CAS#: 288591-93-5

Chemical Formula: C16H25N7O7S

Exact Mass: 459.1536

Molecular Weight: 459.48

Elemental Analysis: C, 41.82; H, 5.48; N, 21.34; O, 24.37; S, 6.98

Price and Availability

Size Price Availability Quantity
1mg USD 410.00 2 Weeks
5mg USD 1,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Leu-AMS
IUPAC/Chemical Name
((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl (L-leucyl)sulfamate
InChi Key
XFEDFDTWJLGMBO-LEJQEAHTSA-N
InChi Code
InChI=1S/C16H25N7O7S/c1-7(2)3-8(17)15(26)22-31(27,28)29-4-9-11(24)12(25)16(30-9)23-6-21-10-13(18)19-5-20-14(10)23/h5-9,11-12,16,24-25H,3-4,17H2,1-2H3,(H,22,26)(H2,18,19,20)/t8-,9+,11+,12+,16+/m0/s1
SMILES Code
O[C@@H]([C@H]([C@H](N1C=NC2=C1N=CN=C2N)O3)O)[C@H]3COS(=O)(NC([C@@H](N)CC(C)C)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Leu-AMS is a potent inhibitor of leucyl-tRNA synthetase (LRS) with an IC50 of 22.34 nM.
In vitro activity:
Compound 18 (Leu-AMS) selectively inhibited LRS-mediated mTORC1 activation and exerted specific cytotoxicity against colon cancer cells with a hyperactive mTORC1, suggesting that 18 may offer a novel treatment option for human colorectal cancer. Reference: J Med Chem. 2016 Nov 23;59(22):10322-10328. https://pubmed.ncbi.nlm.nih.gov/27933890/
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMSO 49.2 107.01
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 459.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Yoon S, Kim JH, Kim SE, Kim C, Tran PT, Ann J, Koh Y, Jang J, Kim S, Moon HS, Kim WK, Lee S, Lee J, Kim S, Lee J. Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors. J Med Chem. 2016 Nov 23;59(22):10322-10328. doi: 10.1021/acs.jmedchem.6b01190. Epub 2016 Nov 9. PMID: 27933890.
In vitro protocol:
1. Yoon S, Kim JH, Kim SE, Kim C, Tran PT, Ann J, Koh Y, Jang J, Kim S, Moon HS, Kim WK, Lee S, Lee J, Kim S, Lee J. Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors. J Med Chem. 2016 Nov 23;59(22):10322-10328. doi: 10.1021/acs.jmedchem.6b01190. Epub 2016 Nov 9. PMID: 27933890.
In vivo protocol:
TBD
1. Yoon S, et al. Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-TargetedMammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors. J Med Chem. 2016 Nov 23;59(22):10322-10328.